Sight Sciences Files 8-K on Security Holder Vote

TL;DR

Sight Sciences is having a shareholder vote on June 6th.

AI Summary

On June 6, 2024, Sight Sciences, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The filing does not disclose specific details about the matters to be voted on or the outcome of any vote, but it confirms that a vote of security holders is scheduled or has occurred.

Why It Matters

This filing indicates that Sight Sciences is engaging its shareholders in a formal voting process, which is a standard corporate governance procedure but can sometimes signal significant corporate actions or changes.

Risk Assessment

Risk Level: low — The filing is a routine procedural update regarding a security holder vote and does not contain information that inherently increases risk.

Key Players & Entities

• Sight Sciences, Inc. (company) — Registrant
• June 6, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT Nasdaq Glo

Filing Documents

• sght-20240606.htm (8-K) — 70KB
• 0000950170-24-070062.txt ( ) — 197KB
• sght-20240606.xsd (EX-101.SCH) — 33KB
• sght-20240606_htm.xml (XML) — 5KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 6, 2024, Sight Sciences, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). There were 49,745,926 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting at the close of business on April 9, 2024, the record date for the Annual Meeting (the "Record Date"). At the Annual Meeting, 37,992,075 shares of Common Stock were present virtually or represented by proxy, representing approximately 76.37% of the Common Stock outstanding on the Record Date. Set forth below are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which are described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024. Proposal 1 – Election of three Class III directors to serve as directors of the Company until the annual meeting of stockholders to be held in 2027, or until each such director's respective successor has been duly elected and qualified, or until each such director's earlier death, resignation or removal. Name of Director For Withheld Broker Non-Votes David Badawi, M.D. 29,546,441 616,495 7,829,139 Tamara Fountain, M.D. 25,188,027 4,974,909 7,829,139 Donald Zurbay 27,133,745 3,029,191 7,829,139 Proposal 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstain Broker Non-Votes 37,537,569 334,310 120,196 - Based on the foregoing votes, David Badawi, M.D., Tamara Fountain, M.D. and Donald Zurbay were elected as Class III directors, and the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: June 6, 2024 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR